Mounjaro (tirzepatide), is the popular weight-loss injection taking the world by storm. It has proven to be the most effective weight-loss solution, with trials demonstrating an impressive 22.5% reduction in weight after 72 weeks. While Mounjaro has shown to be highly effective in helping patients manage blood glucose levels and achieve weight loss, it is not suitable for everyone. Who should not take Mounjaro? This article will explore the key groups of people who should not take Mounjaro.
-
Mounjaro 15mg Injection£229.99 – £899.99 -
Mounjaro 10mg Injection£185.99 – £735.99 -
Mounjaro 5mg Injection£145.99 – £565.99
Who should not take Mounjaro- summary
- People with a known allergy to tirzepatide or any of the other ingredients in Mounjaro.
- Pregnant or breastfeeding women
- Children under 18 years of age
- Individuals with a history of medullary thyroid cancer (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2)
- Individuals with a history of severe gastrointestinal issues, such as:
- Gastroparesis (delayed stomach emptying)
- Pancreatitis (inflammation of the pancreas)
- Individuals with severe kidney or liver problems
- People with diabetic retinopathy
Always consult a healthcare provider before starting Mounjaro, especially if you have any of the above conditions. If you are unsure if Mounjaro is suitable for you contact us for your FREE Mounjaro weight-loss consultation.
Before we go into more depth about who should not take Mounjaro, we will just do a quick recap on Mounjaro itself.
What is Mounjaro?
Mounjaro belongs to the class of weight loss drugs known as the incretins. The first such drug was Wegovy which contained the active ingredient semaglutide, which mimicked the effect of a natural incretin, glucagon-like peptide (GLP-1).
Mounjaro contains the active ingredient, tirzepatide, which goes one better than Wegovy, in that it activates two incretins, GLP-1 and glucose-dependent insulinotropic peptide (GIP). Since it combines the effects of both GLP-1 and GIP, it is called a “twincretin”.
How does Mounjaro cause weight loss?
Mounjaro works in two ways by mimicking the actions of GLP-1 and GIP hormones: it helps lower blood sugar levels in people with type 2 diabetes and supports weight loss by curbing hunger and enhancing feelings of fullness.
When two is better than one, the effects of GLP-1 and GIP
Recognising the promising results, Eli Lilly patented tirzepatide in 2016 and later confirmed its effectiveness for weight loss in humans through the SURMOUNT trials.
How effective is Mounjaro?
In the SURMOUNT 1 trial, over 72 weeks, those taking the highest dose of Mounjaro (15 mg) experienced an average weight loss of 22.5% of their body weight, with nearly 90% of participants losing at least 5% of their body weight.
The results from the SURMOUNT 1 trial are summarized in the table below.
| Week | Tirzepatide (5mg) | Tirzepatide(10mg) | Tirzepatide (15mg) | Placebo |
| 0 | 105 kg | 105 kg | 105 kg | 105 kg |
| 4 | 101 kg | 100.5 kg | 100 kg | 104.5 kg |
| 8 | 96.5 kg | 95.5 kg | 95 kg | 104 kg |
| 12 | 93.5 kg | 91.5 kg | 90 kg | 103.5 kg |
| 16 | 91.5 kg | 89 kg | 87 kg | 103 kg |
| 24 | 90 kg | 86 kg | 84.5 kg | 102.5 kg |
| 36 | 89.3 kg | 84.5 kg | 83 kg | 102.4 kg |
| 48 | 89 kg | 83.5 kg | 82 kg | 102.4 kg |
| 72 | 88.6 kg | 82.6 kg | 81.2 kg | 102.4 kg |
Have questions about Mounjaro?
Get a FREE telephone consultation with one of our pharmacists, who will call you and help you understand what the right options are for you.
Call me about Mounjaro
| Week | Tirzepatide (5mg) | Tirzepatide(10mg) | Tirzepatide (15mg) | Placebo |
| 0 | 231 lbs | 231 lbs | 231 lbs | 231 lbs |
| 4 | 222.2 lbs | 221.3 lbs | 220.5 lbs | 230 lbs |
| 8 | 212.7 lbs | 210.5 lbs | 209.4 lbs | 229 lbs |
| 12 | 206 lbs | 201.6 lbs | 198.4 lbs | 228 lbs |
| 16 | 201.6 lbs | 196.2 lbs | 191.8 lbs | 227 lbs |
| 24 | 198.4 lbs | 189.6 lbs | 186.2 lbs | 226 lbs |
| 36 | 196.8 lbs | 186.3 lbs | 183 lbs | 225.8 lbs |
| 48 | 196.2 lbs | 184 lbs | 180.7 lbs | 225.8 lbs |
| 72 | 195.3 lbs | 182.1 lbs | 179 lbs | 225.8 lbs |
Who should not take Mounjaro?
In clinical trials, Mounjaro has shown to be effective in helping patients lose significant amounts of weight, making it a promising option for those struggling with obesity and associated metabolic conditions.
Despite its efficacy, Mounjaro is not without limitations, and certain populations must be cautious or avoid using this medication altogether. Let’s examine the groups of people who should not take Mounjaro.
The prescribing information for Mounjaro lists the individuals who should not take Mounjaro. Although people with a history of medullary thyroid cancer or MEN are not included, we have included them in our list based on our clinical judgement.
1. Individuals with an allergy to Mounjaro or tirzepatide or any of the other ingredients
One of the most important considerations when taking any medication is the potential for allergic reactions.
Mounjaro contains tirzepatide as its active ingredient, and like any drug, it can cause allergic reactions in some individuals. If a person is allergic to tirzepatide or any of the other ingredients in Mounjaro, they should not take the medication.
Allergic reactions to tirzepatide are relatively rare, but they can range from mild symptoms like rash, itching, or swelling to more severe reactions, such as difficulty breathing or anaphylaxis.
It is important for individuals to carefully read the full list of ingredients and consult with their healthcare provider to determine whether they have any known allergies to the components of Mounjaro.
An allergic reaction can be life-threatening if not treated promptly, so individuals who experience symptoms such as hives, swelling of the face or throat, or difficulty breathing after taking Mounjaro should seek immediate medical attention.
2. Pregnant or breastfeeding women
Mounjaro is not recommended for pregnant or breastfeeding women. The safety of tirzepatide during pregnancy and breastfeeding has not been established.
In animal studies, tirzepatide caused problems with baby growth and abnormalities at doses lower than what would be used in humans. In rats, there were more cases of malformations in the outside and internal organs, as well as in the bones. Rats and rabbits also showed signs of reduced growth in their babies. These issues occurred only at doses that were harmful to the mother.
As a result, pregnant women should not take Mounjaro.
For breastfeeding women, there is insufficient data to determine whether tirzepatide passes into breast milk, and if it does, what impact it could have on a nursing infant.
As a result, it is advised that breastfeeding women should not take Mounjaro.
3. Children under 18 years of age
Mounjaro is not recommended for use in children under the age of 18.
4. Individuals with a history of severe gastrointestinal issues
Mounjaro works by mimicking the effects of incretin hormones that influence gastrointestinal motility. As a result, Mounjaro can have significant effects on the digestive system, including slowing gastric emptying and reducing appetite.
While these effects can be beneficial for individuals with obesity or type 2 diabetes, they can be problematic for individuals with certain gastrointestinal conditions.
People with a history of severe gastrointestinal issues, such as gastroparesis or pancreatitis, should avoid taking Mounjaro.
What is gastroparesis?
Gastroparesis is a condition where the stomach cannot empty properly, leading to nausea, vomiting, and bloating.
What is pancreatitis?
Pancreatitis is inflammation of the pancreas that can cause severe abdominal pain, vomiting, and digestive issues.
Both conditions, gastroparesis and pancreatitis can be worsened by medications that slow gastric motility or affect digestive function, making Mounjaro unsuitable for individuals with these conditions.
If you have a history of pancreatitis, or if you have been diagnosed with any gastrointestinal disorder that affects your digestion, it is essential to discuss these conditions with your healthcare provider before starting Mounjaro.
In some cases, alternative treatments for type 2 diabetes or obesity may be more appropriate.
5. Individuals with kidney or liver issues
Individuals with kidney or liver disease should exercise caution when taking Mounjaro, as the medication is processed by these organs.
Mounjaro has not been studied extensively in people with severe kidney or liver impairment, and there may be an increased risk of side effects in these populations.
If you have chronic kidney disease (CKD) or liver disease, your doctor will carefully assess your individual health status before prescribing Mounjaro.
It may be necessary to adjust the dosage or monitor kidney and liver function more closely throughout treatment. In some cases, other medications or treatments may be more suitable.
6. Individuals with diabetic retinopathy
Diabetic retinopathy is a complication of diabetes that affects the blood vessels in the retina, potentially leading to vision problems or blindness.
While Mounjaro can help manage blood sugar levels and reduce the risk of diabetic complications, its effects on diabetic retinopathy have not been fully studied.
People with advanced diabetic retinopathy or other serious eye conditions related to diabetes should consult with their healthcare provider before starting Mounjaro.
In some cases, intensive management of blood sugar levels may be required to prevent further damage to the eyes, and other treatments may be recommended.
7. Individuals with a history of medullary thyroid cancer or MEN
Animal studies have shown that high doses of GLP-1 medications led to thyroid tumors in rodents., but this risk may not apply to humans.
Unlike rodents, humans and primates have very few or no GLP-1 receptors on their thyroid , which means the same effects are unlikely to happen in people.
A recent study published in the BMJ on April 10, 2024 supports this, showing that GLP-1 medications used for diabetes and weight loss do not significantly increase the risk of thyroid cancer in humans.
The study followed over 145,000 people using GLP-1 medications and found a very low occurrence of thyroid cancer, suggesting the risk is minimal.
In summary, while animal studies raised concerns, recent human research shows a low risk of thyroid cancer with GLP-1 medications.
However, that being said we would advise that people who have had medullary thyroid cancer or MEN (Multiple endocrine neoplasia) or have a family history, should not take Mounjaro.
Who should not take Mounjaro conclusion
Mounjaro is a powerful medication that can help individuals with obesity or type 2 diabetes manage their blood sugar and achieve weight loss. However, it is not suitable for everyone, and there are several important factors to consider before starting treatment.
Individuals with allergies to tirzepatide or any of its components, pregnant or breastfeeding women, children under 18, and those with certain gastrointestinal, kidney, liver, or eye conditions should avoid using Mounjaro.
People with either a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (MEN) should also not take Mounjaro.
Before starting Mounjaro, it is essential to consult with a healthcare provider who can assess your health profile and determine whether the medication is appropriate for you.
This ensures that you are receiving the safest and most effective treatment for your condition while minimising potential risks.
Not sure if you can take Mounjaro?
If you are still unsure if Mounjaro is safe for you, please contact us for your FREE Mounjaro weight loss consultation.
Who should not take Mounjaro summary:
- Allergic to tirzepatide or its ingredients
- Pregnant or breastfeeding women
- Children under 18
- History of medullary thyroid cancer (MTC) or MEN 2
- Severe gastrointestinal issues (e.g., gastroparesis, pancreatitis)
- Severe kidney or liver problems
- Diabetic retinopathy
What are the next steps?
Complete the online health questionnaire to confirm that Mounjaro is suitable for you. One of our prescribers will review your order and then issue a prescription. Once you make payment, our pharmacy will dispense and dispatch your delivery direct to your doorstep.
Click here to book a weight-loss consultation with Medical Mojo.
Are weight loss treatments making you tired, or have they led to a sudden increase in hair loss? Do you struggle with sleep?
Get a free month’s supply of one of our compounded treatments for energy, hair loss or sleep, with your first purchase of Mounjaro or Wegovy from Medical Mojo.
Claim your FREE offer
Who is Mounjaro licensed for?
Mounjaro, the brand name for tirzepatide, is a newly approved weekly injection for weight loss, authorised by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA 2023) in November 2023.
It is licensed for adults with obesity (BMI > 30) or those who are overweight (BMI 27–30) with weight-related health conditions, such as prediabetes, high blood pressure, high cholesterol, or heart problems.
The medicine is to be used together with a reduced-calorie diet and increased physical activity (MHRA 2023)
activity MHRA 2023)
Frequently asked questions about Mounjaro
Can I drink alcohol while using Mounjaro?
It’s recommended to reduce alcohol intake while using Mounjaro, as alcohol can increase the likelihood of side effects like nausea or dizziness. For more information, read our blog, “Can you drink alcohol while taking Mounjaro?”
Does Mounjaro cause thyroid cancer?
Though there were concerns based on rodent studies, there is very little evidence to suggest Mounjaro causes thyroid cancer. Learn more in our blog, “Does Mounjaro cause thyroid cancer?”
Does Mounjaro cause hair loss?
Hair loss occurs in about 5% of individuals taking Mounjaro. However, it’s unclear whether this is due to Mounjaro itself or rapid weight loss. Find out more in our blog, “Does Mounjaro cause hair loss?”
How long do the side effects of Mounjaro last?
When starting Mounjaro, you may experience side effects like nausea, bloating, and constipation. To help your body adjust, Mounjaro uses a gradual dose escalation process. These side effects typically lessen within a few days or weeks. For more details, read our blog, “How long do the side effects of Mounjaro last?”
Can I start Mounjaro at 5 mg?
No, the starting dose of Mounjaro is 2.5 mg. It’s important to follow the recommended dosing schedule to minimize side effects and allow your body to adjust safely.
Is Mounjaro 15mg the only maintenance dose?
No, Mounjaro has three maintenance doses:
- Mounjaro 5mg
- Mounjaro 10mg
- Mounjaro 15mg
To learn more about the maintenance doses, read our blog, “Mounjaro maintenance doses”.
Can Mounjaro help with PCOS?
It has been demonstrated that PCOS can be improved with weight loss and increased insulin sensitivity. Since Mounjaro ticks both these boxes, it can help with PCOS, although more studies are required. To learn more, read our blog, Mounjaro and PCOS.
Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice.
References:
- Bokvist, K.B., Finan, B., Friedrichsen, S., & Heise, T. (2016). Glucagon-like peptide-1 receptor (GLP-1R) agonists combined with glucose-dependent insulinotropic peptide (GIP) receptor agonists for the treatment of metabolic disorders. United States Patent US9474780B2. Retrieved from https://patents.google.com/patent/US9474780/en.
- ClinicalTrials.gov. (2021). SURMOUNT-1: Tirzepatide for Weight Loss in Non-Diabetic Obese Individuals. Retrieved from https://clinicaltrials.gov.
- Chavda, V.P., Ajabiya, J., Teli, D., Bojarska, J. and Apostolopoulos, V., 2022. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules, 27(13), p.4315.
- Coskun, T., et al. (2018). Tirzepatide, a dual GLP-1 and GIP receptor agonist, induces significant weight loss in patients with obesity. Diabetes Care, 41(10), 2100–2108.
- Electronic Medicines Compendium. (n.d.). Mounjaro 2.5 mg, 5 mg, 10 mg, 15 mg solution for injection in pre-filled pen [Summary of Product Characteristics]. Retrieved December 17, 2024, from https://www.medicines.org.uk/emc/product/15481/smpc#about-medicine
- Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M.C. and Stefanski, A., 2022. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), pp.205-216.
- Lars Wichmann Madsen, Jeffrey A. Knauf, Carsten Gotfredsen, Andrew Pilling, Ingrid Sjögren, Søren Andersen, Lene Andersen, Anne Sietske de Boer, Katia Manova, Afsar Barlas, Sushil Vundavalli, Niels C. Berg Nyborg, Lotte Bjerre Knudsen, Anne Marie Moelck, James A. Fagin, GLP-1 Receptor Agonists and the Thyroid: C-Cell Effects in Mice Are Mediated via the GLP-1 Receptor and not Associated with RET Activation, Endocrinology, Volume 153, Issue 3, 1 March 2012, Pages 1538–1547, https://doi.org/10.1210/en.2011-1864
- Pasternak, B., Wintzell, V., Hviid, A., Eliasson, B., Gudbjörnsdottir, S., Jonasson, C., Hveem, K., Svanström, H., Melbye, M. and Ueda, P., 2024. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. bmj, 385.
- Sinha R, Papamargaritis D, Sargeant JA, Davies MJ. Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. J Obes Metab Syndr. 2023 Mar 30;32(1):25-45.
